Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Industry Outlook 2025: A Busy Time Ahead

March 19, 2025

In an interview with Pharmaceutical Technology®, Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.

Shilpa Biologicals and mAbTree Biologics to Collaborate on Novel Immuno-Oncology Asset

March 18, 2025

The partnership aims to develop and commercialize a novel checkpoint inhibitor for immuno-oncology applications.

DCAT Member Companies Present Latest News to Start DCAT Week 2025

March 17, 2025

The Member Company Announcement Forum is the kickoff event of the annual DCAT Week in New York City, which is being held from March 17–20.

Webcasts

Long acting PLGA complex parenterals and IVIVC development

March 11, 2025

Webinar Date/Time: Wed, Mar 26, 2025 1:30 PM EDT

Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles

March 09, 2025

Exosomes, polymeric nanoparticles, and DNA nanostructures offer many potential advantages.

Launching the New Biotech and Biomanufacturing Hub

March 04, 2025

The Biotech and Biomanufacturing Hub will help European companies access funding, navigate regulations, and speed up market access.

Novartis Treatment for C3G Gets Positive Opinion from EMA

March 04, 2025

CHMP gave its opinion and a recommendation for marketing authorization to Fabhalta (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway.

Pushing Tech Boundaries

March 03, 2025

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia

March 03, 2025

Jaypirca (pirtobrutinib) has received a conditional marketing authorization from EMA for mantle cell lymphoma. The drug was approved in the United States in 2023 for several indications.

Rare Disease Day Celebrated on February 28

March 01, 2025

More than 6000 rare diseases—those which affect fewer than one in 2000 people each—are acknowledged in the medical community, with 72% of them being genetic.